US launches research network to evaluate emerging cancer screening technologies

The US National Institutes of Health (NIH) has launched a new clinical trials network, the Cancer Screening Research Network, to evaluate emerging technologies for cancer screening. The network will focus on identifying cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network. The goal is to systematically evaluate cancer screening technologies to ultimately save lives.

According to W. Kimryn Rathmell, director of NCI, “Emerging technologies such as multi-cancer detection tests could transform cancer screening and help to extend the lives of many more people. We need to be sure that these technologies work and understand how to use them so they benefit everyone.” This initiative comes as a response to the growing need for more effective and reliable cancer screening methods.

In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection tests in future randomised controlled trials, according to NIH. “Our goal is to systematically evaluate cancer screening technologies to understand how best to use them to ultimately save lives. Data collected through these clinical trials can be used to develop evidence-based guidelines for cancer screening,” said Lori M. Minasian, deputy director of the Division of Cancer Prevention at NCI.

The Cancer Screening Research Network aims to harness the potential of emerging technologies to revolutionize cancer screening and improve outcomes for patients. With a focus on early detection and effective utilization of these technologies, the network could play a vital role in shaping the future of cancer screening and treatment, providing hope for many individuals and families affected by the disease.